Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Non-Current Assets (2016 - 2025)

Ultragenyx Pharmaceutical has reported Non-Current Assets over the past 11 years, most recently at $581.0 million for Q4 2025.

  • Quarterly Non-Current Assets fell 15.31% to $581.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.3 billion through Dec 2025, down 16.57% year-over-year, with the annual reading at $581.0 million for FY2025, 15.31% down from the prior year.
  • Non-Current Assets was $581.0 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $547.2 million in the prior quarter.
  • Over five years, Non-Current Assets peaked at $758.8 million in Q4 2023 and troughed at $526.8 million in Q1 2021.
  • The 5-year median for Non-Current Assets is $638.4 million (2021), against an average of $636.0 million.
  • Year-over-year, Non-Current Assets skyrocketed 60.93% in 2021 and then dropped 25.92% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $665.8 million in 2021, then fell by 0.64% to $661.5 million in 2022, then increased by 14.71% to $758.8 million in 2023, then dropped by 9.6% to $686.0 million in 2024, then decreased by 15.31% to $581.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Non-Current Assets are $581.0 million (Q4 2025), $547.2 million (Q3 2025), and $586.5 million (Q2 2025).